Jefferies Drops Price Target After ResMed (RMD) Heart Failure Trial Fails
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
Go back to Jefferies Drops Price Target After ResMed (RMD) Heart Failure Trial Fails
May 13, 2015 8:44 AM EDT
BofA/Merrill Lynch downgraded ResMed (NYSE: RMD) from Buy to Neutral. Earlier ResMed announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint.
For an analyst ratings summary and ratings history on ResMed... More
May 13, 2015 6:14 AM EDT
ResMed (NYSE: RMD) announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint. SERVE-HF was designed to assess whether the treatment of moderate to severe predominant central sleep apnea with Adaptive Servo-Ventilation (ASV) therapy could reduce mortality and morbidity in patients with symptomatic chronic heart failure in addition to optimized medical care.
The study did not show a statistically significant difference between patients randomized to ASV therapy and those in the control group in the primary endpoint of time to all-cause mortality or unplanned hospitalization... More
